AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO PAOLO GIACCONE DI PALERMO

Their core work

Policlinico Paolo Giaccone is the main university hospital of Palermo, serving as both a clinical care center and an academic research institution affiliated with the University of Palermo. In H2020, they contributed clinical expertise to infectious disease vaccine development — specifically tuberculosis — and more recently to computational oncology for advanced colorectal cancer. Their role is that of a clinical research partner providing patient access, biobank resources, and medical domain knowledge to larger European research consortia.

What they specialise in

How they've shifted over time

Their early H2020 work (2015-2019) was firmly rooted in infectious disease, with two concurrent tuberculosis projects covering both vaccine candidates and mucosal immune response. By 2020, they shifted toward oncology and computational medicine through the REVERT project, which combines targeted cancer therapy with AI-based predictive modeling. This pivot from infectious disease to data-driven oncology suggests the hospital is following broader biomedical trends toward precision medicine and AI-assisted clinical decision-making.

Moving from traditional infectious disease research toward computational oncology and AI-assisted treatment planning, indicating growing interest in precision medicine approaches.

How they like to work

AOUP has never coordinated an H2020 project, consistently joining as a participant or third party within large consortia. With 78 unique partners across 19 countries from just 3 projects, they operate in very large international networks — typical of major clinical trials and multi-site vaccine studies. This profile suggests they contribute specialized clinical resources (patients, samples, medical expertise) rather than driving project design, making them a reliable clinical validation partner.

Despite only three projects, AOUP has worked with 78 distinct partners across 19 countries, reflecting the large-consortium structure of vaccine and oncology trials. Their network spans broadly across Europe with no obvious geographic concentration beyond Italy.

What sets them apart

As a major Sicilian university hospital, AOUP offers access to a Southern Italian patient population — a demographic often underrepresented in Northern European-led clinical studies. Their dual track record in infectious disease and emerging oncology/AI work makes them versatile for health-sector consortia needing clinical sites. For consortium builders, they bring hospital-based clinical infrastructure without the overhead of coordinating the project themselves.

Highlights from their portfolio

• EMI-TB
  Their largest funded project (EUR 320,000), focused on mucosal immunity to tuberculosis — a specialized immunological angle within TB vaccine research.
• REVERT
  Marks a strategic shift into computational oncology and AI-based decision support for colorectal cancer, signaling new research directions for the hospital.